复星医药(600196.SH)：控股子公司药品HLX15获临床试验批准

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., Ltd., has received approval from the National Medical Products Administration to conduct Phase I clinical trials for HLX15-SC, a recombinant anti-CD38 fully human monoclonal antibody injection for the treatment of multiple myeloma [1] Group 1 - The drug HLX15 is a biosimilar to Daratumumab, developed by the company, and includes both subcutaneous (HLX15-SC) and intravenous (HLX15-IV) formulations intended for the treatment of multiple myeloma [1] - The Phase I clinical study for HLX15-IV in male healthy subjects in China was completed in June 2024 [1]